These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
227 related items for PubMed ID: 31895759
1. The success rate of radioactive iodine therapy for Graves' disease in iodine-replete area and affecting factors: a single-center study. Park H, Kim HI, Park J, Park SY, Kim TH, Chung JH, Choi JY, Kim SW. Nucl Med Commun; 2020 Mar; 41(3):212-218. PubMed ID: 31895759 [Abstract] [Full Text] [Related]
2. Changes in Thyrotropin Receptor Antibody Levels Following Total Thyroidectomy or Radioiodine Therapy in Patients with Refractory Graves' Disease. Kim J, Choi MS, Park J, Park H, Jang HW, Choe JH, Kim JH, Kim JS, Cho YS, Choi JY, Kim TH, Chung JH, Kim SW. Thyroid; 2021 Aug; 31(8):1264-1271. PubMed ID: 33947272 [Abstract] [Full Text] [Related]
3. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period. Kaplowitz PB, Jiang J, Vaidyanathan P. J Pediatr Endocrinol Metab; 2020 Mar 26; 33(3):383-389. PubMed ID: 31603857 [Abstract] [Full Text] [Related]
5. High Thyroid Stimulating Receptor Antibody Titre and Large Goitre Size at First-Time Radioactive Iodine Treatment are Associated with Treatment Failure in Graves' Disease. Tay WL, Chng CL, Tien CS, Loke KS, Lam WW, Fook-Chong SM, Tong AK. Ann Acad Med Singap; 2019 Jun 26; 48(6):181-187. PubMed ID: 31377762 [Abstract] [Full Text] [Related]
8. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, Rossi G, Ceccarelli C, Vitti P, Pinchera A, Bartalena L, Martino E. J Clin Endocrinol Metab; 2010 Jan 26; 95(1):201-8. PubMed ID: 19906789 [Abstract] [Full Text] [Related]
9. Evidence for higher success rates and successful treatment earlier in Graves' disease with higher radioactive iodine doses. Sztal-Mazer S, Nakatani VY, Bortolini LG, Boguszewski CL, Graf H, de Carvalho GA. Thyroid; 2012 Oct 26; 22(10):991-5. PubMed ID: 22953990 [Abstract] [Full Text] [Related]
10. Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves' disease. Sawicka N, Sowiński J. Endokrynol Pol; 2012 Oct 26; 63(1):10-3. PubMed ID: 22378091 [Abstract] [Full Text] [Related]
14. Treatment Patterns and Preferences for Graves' Disease in Korea: Insights from a Nationwide Cohort Study. Kim KJ, Choi J, Shin SM, Kim JA, Kim KJ, Kim SG. Endocrinol Metab (Seoul); 2024 Aug 26; 39(4):659-663. PubMed ID: 39099390 [Abstract] [Full Text] [Related]
18. Radioactive Iodine Therapy of Graves' Disease in Patients Pretreated With Methimazole Without Radioiodine Uptake for Dose Estimation. Mihailescu DV, Hoscheit C, Fogelfeld L. Endocr Pract; 2024 Apr 26; 30(4):333-339. PubMed ID: 38307459 [Abstract] [Full Text] [Related]
19. The occurrence of hypothyroidism following radioactive iodine treatment of toxic nodular goiter is related to the TSH level. Adamali HI, Gibney J, O'Shea D, Casey M, McKenna TJ. Ir J Med Sci; 2007 Sep 26; 176(3):199-203. PubMed ID: 17632747 [Abstract] [Full Text] [Related]
20. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Walter MA, Christ-Crain M, Eckard B, Schindler C, Nitzsche EU, Müller-Brand J, Müller B. Eur J Clin Invest; 2004 May 26; 34(5):365-70. PubMed ID: 15147334 [Abstract] [Full Text] [Related] Page: [Next] [New Search]